The Limited Times

Now you can see non-English news...

Corona vaccine: Former Bayer plant in Wuppertal cannot start production until the end of 2021

2021-01-15T13:04:48.915Z


In order to quickly manufacture more corona vaccines, politicians and pharmaceutical companies are urgently looking for production capacities. A former Bayer plant in Wuppertal is supposed to help, but it cannot start until late.


Icon: enlarge

Bayer logo in Wuppertal

Photo: 

INA FASSBENDER / REUTERS

The factory in Wuppertal, sold by Bayer to Wuxi Biologics, will not bring relief from the Covid-19 vaccine bottleneck.

Wuxi expects the transaction to be approved in the first half of the year.

You also have to make modifications to the factory first.

The system could therefore only be commissioned at the end of 2021.

In addition, the plant in which Bayer originally wanted to produce the coagulation factor Kovaltry is not allowed to produce any new types of mRNA vaccines from Biontech (Mainz) or Curevac (Tübingen).

Wuxi says it has signed a supply agreement with British-Swedish pharmaceutical company AstraZeneca to manufacture AZD1222, an adenovirus-based vector vaccine against Covid-19.

AstraZeneca has just filed for approval for the vaccine with the European Medicines Agency.

In Great Britain, the vaccine received an emergency approval on December 30, 2020. An approval decision for the European Union is expected for January 29, 2021.

more on the subject

  • Corona news on Monday: 60,000 doses of Moderna vaccine arrived in Germany

  • Corona vaccinations: Biontech vaccine will soon also be produced in Halle, Westphalia

  • Federal Minister of Health: Spahn promises vaccinations for all citizens by the summer

The effectiveness of AZD1222 was lower than that of mRNA vaccines in one study.

The vaccine can be stored at refrigerator temperatures, and at around two euros per dose, it is significantly cheaper than the products from Biontech or Curevac.

There was initially criticism of the published study data, also because the average values ​​of two different studies were used.

Bayer had never put the plant in Wuppertal into operation itself and sold it to a German subsidiary of Wuxi Biologics in December 2020.

The Chinese company had previously taken over another Bayer production facility in Leverkusen.

According to Wuxi, the hope is to be able to use synergies from both production sites.

The facility for pharmaceutical products in Leverkusen is able to fill and freeze-dry up to ten million vials per year in a sterile manner.

Icon: The mirror

Source: spiegel

All business articles on 2021-01-15

You may like

News/Politics 2024-03-16T18:46:42.470Z
News/Politics 2024-03-18T14:18:09.201Z
News/Politics 2024-03-08T10:38:27.179Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.